Validation of the dyspnoea‐12 scale into <scp>P</scp>ortuguese speaking <scp>COPD</scp> patients

Simsic, Aline Aparecida; Yorke, Janelle; Regueiro, Eloisa Gatti; Lorenzo, Valéria Pires Di; Martinez, José Antônio Baddini

doi:10.1111/crj.12762

Cited by 12 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reliability was acceptable at 0.81 although it did not fully reach the optimal level of 0.90 which was reported in the original validation study 11. The concurrent validity was consistent with previously reported correlations of D-12 with HADS, mMRC, CAT and forced expiratory volume in 1 s, in the English, Arabic and Portuguese validation studies 11–13 16 17 19…”

Section: Discussionsupporting

confidence: 83%

“…The original English version has been validated by the developer in patients with COPD, heart failure, interstitial lung diseases, asthma, pulmonary arterial hypertension and lung cancer 11–15. D-12 is now also available in Arabic,16 17 Korean,18 Portuguese,19 Italian20 and Swedish,21 which is important to enable the comparison of results between countries.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical validation of the Swedish version of Dyspnoea-12 instrument in outpatients with cardiorespiratory disease

Sundh

Bornefalk²,

Sköld

et al. 2019

BMJ Open Resp Res

View full text Add to dashboard Cite

IntroductionBreathlessness is the cardinal symptom in both cardiac and respiratory diseases, and includes multiple dimensions. The multidimensional instrument Dyspnoea-12 has been developed to assess both physical and affective components of breathlessness. This study aimed to perform a clinical validation of the Swedish version of Dyspnoea-12 in outpatients with cardiorespiratory disease.MethodsStable outpatients with cardiorespiratory disease and self-reported breathlessness in daily life were recruited from five Swedish centres. Assessments of Dyspnoea-12 were performed at baseline, after 30–90 min and after 2 weeks. Factor structure was tested using confirmatory factor analysis and internal consistency using Cronbach’s alpha. Test–retest reliability was analysed using intraclass correlation coefficients (ICCs). Concurrent validity at baseline was evaluated by examining correlations with lung function and several instruments for the assessment of symptoms and health status.ResultsIn total, 182 patients were included: with the mean age of 69 years and 53% women. The main causes of breathlessness were chronic obstructive pulmonary disease (COPD; 25%), asthma (21%), heart failure (19%) and idiopathic pulmonary fibrosis (19%). Factor analysis confirmed the expected underlying two-component structure with two subdomains. The Dyspnoea-12 total score, physical subdomain score and affective subdomain scores showed high internal consistency (Cronbach’s alpha 0.94, 0.84 and 0.80, respectively) and acceptable reliability after 2 weeks (ICC total scores 0.81, 0.79 and 0.73). Dyspnoea-12 showed concurrent validity with the instruments modified Medical Research Council scale, COPD Assessment Test, European Quality of Life-Five Dimensions-Five levels, the Functional Assessment of Chronic Illness Therapy-Fatigue, the Hospital Anxiety and Depression Scale, and with forced expiratory volume in 1 s in percentage of predicted value. The results were consistent across different cardiorespiratory conditions.ConclusionThe Dyspnoea-12 is a valid instrument for multidimensional assessment of breathlessness in Swedish patients with cardiorespiratory diseases.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

Clinical validation of the Swedish version of Dyspnoea-12 instrument in outpatients with cardiorespiratory disease

Sundh

Bornefalk²,

Sköld

et al. 2019

BMJ Open Resp Res

View full text Add to dashboard Cite

show abstract

“…Studies were conducted across 18 different countries, with the most frequent being the United Kingdom, United States of America and France. Language translations with psychometric assessments were reported for the D-12 in eight studies (Korean [45], French [24], Brazilian Portuguese [25], Spanish [26], Arabic [38,39], Italian [27], Swedish [20]) and for the MDP in three studies (Brazilian Portuguese [56], Swedish [57], Turkish [86]). The D-12 was more commonly used in observational/descriptive approaches (24 datasets, 73%), whereas the MDP was more frequently used to assess intervention effects ( 18datasets, 49%).…”

Section: Study Focus and Designsmentioning

confidence: 99%

“…Where test-retest was reported (Supplemental materials Table S4), time frames between testing included same day (within hours), between days, or between one to two weeks. For the D-12, the Total score was the most frequently reported [4,20,24,25,26,38,41,43,44] [Figure 2]…”

Section: Reliabilitymentioning

confidence: 99%

Dyspnoea-12 and Multidimensional Dyspnea Profile: Systematic Review of Use and Properties

Williams

Lewthwaite

Paquet

et al. 2022

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…At baseline, each patient underwent clinical examination, arterial blood gases analysis (GEM Premier 3500, United States), and Pulmonary Function Tests (PFTs) (Master screen Diffusion, Jaeger, Germany): spirometry (pre/post-bronchodilation), diffusing capacity and static lung volumes. Dyspnea was assessed by both the modified Medical Research Council (MRC) scale (Simsic et al, 2018) and the COPD Assessment Test (CAT) (Jo et al, 2018). QOL was assessed by the St. George Respiratory Questionnaire (SGRQ) (Oliveira and Marques, 2017).…”

Section: Methodsmentioning

confidence: 99%

Subjective and Objective Outcomes in Patients With COPD After Pulmonary Rehabilitation – The Impact of Comorbidities

Charikiopoulou

Nikolaidis²,

Knechtle

et al. 2019

Front. Physiol.

View full text Add to dashboard Cite

Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease with multiple systemic manifestations and comorbidities, which contribute independently to its total morbidity and mortality. Pulmonary rehabilitation is an evidence-based intervention that is indicated for COPD patients who remain symptomatic, despite optimal pharmacological therapy. Although it is well documented in pure COPD, the role of pulmonary rehabilitation is uncertain in coexisting comorbidities. The aim of the present study was to clarify the effect of a pulmonary rehabilitation program in COPD patients with concomitant comorbidities. Methods: Thirty two patients with COPD were evaluated before and after a comprehensive pulmonary rehabilitation program, in terms of dyspnea, quality of life (QOL), pulmonary function tests and exercise capacity. The patients were also divided into two groups, according to the presence or the absence of comorbidities. Patients with none or only one comorbidity (Group 1, n = 11) were compared to those who had two or more comorbidities (Group 2, n = 21). Results: All patients significantly improved in dyspnea, as expressed by modified Medical Research Council scale and the COPD assessment Test ( p < 0.001), QOL as assessed by the St. George respiratory questionnaire ( p < 0.001) and exercise tolerance in six minute walking test ( p < 0.001). Peak oxygen uptake relatively increased and body mass decreased in Group 1 compared to Group 2 ( p < 0.05). Conclusion: Pulmonary rehabilitation in COPD seems to be beneficial for all patients, independently of the presence, the number or the nature of their comorbidities. Thus, the presence of comorbidities must not represent an exclusion criterion for patients that are referred to pulmonary rehabilitation programs. Trial Registration: Current controlled trials ISRCTN14648515 Retrospectively registered 15 February 2018.

show abstract

Validation of the dyspnoea‐12 scale into Portuguese speaking COPD patients

Abstract: The scale Dyspnoea-12-Pt exhibits acceptable psychometric properties and may be used as an evaluation tool of dyspnea in Portuguese speaking COPD patients.

Cited by 12 publications

References 25 publications

Clinical validation of the Swedish version of Dyspnoea-12 instrument in outpatients with cardiorespiratory disease

Clinical validation of the Swedish version of Dyspnoea-12 instrument in outpatients with cardiorespiratory disease

Dyspnoea-12 and Multidimensional Dyspnea Profile: Systematic Review of Use and Properties

Subjective and Objective Outcomes in Patients With COPD After Pulmonary Rehabilitation – The Impact of Comorbidities

Contact Info

Product

Resources

About